Emerging drugs in multiple myeloma

Bibliography

• JEMAL A, MURRAY T, WARD E et al.: Cancer statistics. CA Cancer J. Clin. (2005) 55(1):10-30.
   PubMed Web of Science ®Google Scholar
• KYLE RA, RAJKUMAR SV: Multiple myeloma. N. Engl. J. Med. (2004) 351(18):1860-1873.
   PubMed Web of Science ®Google Scholar
• ANDERSON KC: Clinical update: novel targets in multiple myeloma. Semin. Oncol. (2004) 31(6 Suppl. 16):27-32.
   PubMedGoogle Scholar
• ANDERSON KC: Moving disease biology from the lab to the clinic. Cancer (2003) 97(3 Suppl.):796-801.
   PubMed Web of Science ®Google Scholar
• ANDERSON KC: Multiple myeloma: how far have we come? Mayo Clin. Proc. (2003) 78(1):15-17.
   PubMed Web of Science ®Google Scholar
• KYLE RA: Five decades of therapy for multiple myeloma: a paradigm for therapeutic models. Leukemia (2005) 19(6):910-912.
   PubMed Web of Science ®Google Scholar
• KUMAR S, RAJKUMAR SV: Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur. J. Cancer (2006).
   Google Scholar
• RICHARDSON PG, MITSIADES C, HIDESHIMA T, ANDERSON KC: Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. (2006) 57:33-47.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, MITSIADES C, HIDESHIMA T, ANDERSON KC: Novel biological therapies for the treatment of multiple myeloma. Best Pract. Res. Clin. Haematol. (2005) 18(4):619-634.
   PubMed Web of Science ®Google Scholar
• ATTAL M, HAROUSSEAU JL, STOPPA AM et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. (1996) 335(2):91-97.
   PubMed Web of Science ®Google Scholar
• ATTAL M, HAROUSSEAU JL, FACON T et al.: Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. (2003) 349(26):2495-2502.
   PubMed Web of Science ®Google Scholar
• HAROUSSEAU JL: Stem cell transplantation in multiple myeloma (0, 1 or 2). Curr. Opin. Oncol. (2005) 17(2):93-98.
   PubMed Web of Science ®Google Scholar
• SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341(21):1565-1571.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV: Thalidomide: tragic past and promising future. Mayo Clin. Proc. (2004) 79(7):899-903.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, CHAUHAN D, SHIMA Y et al.: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 96(9):2943-2950.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, FONSECA R, DISPENZIERI A et al.: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin. Proc. (2000) 75(9):897-901.
   PubMed Web of Science ®Google Scholar
• WEBER D, RANKIN K, GAVINO M, DELASALLE K, ALEXANIAN R.: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. (2003) 21(1):16-19.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, HAYMAN S, GERTZ MA et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. (2002) 20(21):4319-4323.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, BLOOD E, VESOLE D, FONSECA R, GREIPP PR; EASTERN COOPERATIVE ONCOLOGY GROUP: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. (2006) 24(3):431-436.
   PubMed Web of Science ®Google Scholar
• GHOBRIAL IM, RAJKUMAR SV: Management of thalidomide toxicity. J. Support Oncol. (2003) 1(3):194-205.
   PubMedGoogle Scholar
• PALUMBO A, BRINGHEN S, CARAVITA T et al.: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet (2006) 367(9513):825-831.
   PubMed Web of Science ®Google Scholar
• FACON T, MARY J, HAROUSSEAU J et al.: Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J. Clin. Oncol. (2006).
   Google Scholar
• ZERVAS K, MIHOU D, KATODRITOU I et al.: VAD-doxil vs VAD-doxil plus thalidomide as initial treatment in patients with multiple myeloma: a multicenter randomized trial of the Greek Myeloma Study Group. Blood (2006) 238(22a):abstract 794.
   Google Scholar
• ATTAL M, HAROUSSEAU JL, LEYVRAZ S et al.: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 108(10):3289-3294.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, MITSIADES C, HIDESHIMA T, ANDERSON KC.: Lenalidomide in multiple myeloma. Expert Rev. Anticancer Ther. (2006) 6(8):1165-1173.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS MA, SPENCER A, ATTAL M et al.: Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a Phase III study (MM010). Blood (2005) 106:106.
   Google Scholar
• WEBER D, CHEN C, NIESVIZKY M et al.: Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American Phase III study (MM-009). J. Clin. Oncol. (2006).
   Google Scholar
• RAJKUMAR SV, HAYMAN SR, LACY MQ et al.: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 106(13):4050-4053.
   PubMed Web of Science ®Google Scholar
• PALUMBO A, FALCO P, FALCONE A et al.: Oral revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter Phase I/II study. Blood (2006) 108(11) abstract.
   Google Scholar
• KNOP S, GERECKE C, TOPP M et al.: Lenalidomide (revlimid), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma first results of a german multicenter Phase I/II trial. Blood (2006) 108(11) abstract.
   Google Scholar
• SCHEY SA, FIELDS P, BARTLETT JB et al.: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. (2004) 22(16):3269-3276.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, HIDESHIMA T, ANDERSON KC: Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control (2003) 10(5):361-369.
   PubMedGoogle Scholar
• RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. (2003) 348(26):2609-2617.
   PubMed Web of Science ®Google Scholar
• JAGANNATH S, BARLOGIE B, BERENSON J et al.: A Phase II study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. (2004) 127(2):165-172.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, SONNEVELD P, SCHUSTER MW et al.; ASSESSMENT OF PROTEASOME INHIBITION FOR EXTENDING REMISSIONS (APEX) INVESTIGATORS: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. (2005) 352(24):2487-2498.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, MITSIADES C, GHOBRIAL I, ANDERSON K: Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr. Opin. Oncol. (2006) 18(6):598-608.
   PubMed Web of Science ®Google Scholar
• ANDERSON K, RICHARDSON P, CHANAN-KHAN A et al.: Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a Phase II multicenter study. J. Clin. Oncol. (2006) 24(18S):7504.
   Google Scholar
• JAGANNATH S, RICHARDSON PG, BARLOGIE B et al.; SUMMIT/CREST INVESTIGATORS: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 91(7):929-934.
   PubMed Web of Science ®Google Scholar
• JAGANNATH S, DURIE BG, WOLF J et al.: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol. (2005) 129(6):776-783.
   PubMed Web of Science ®Google Scholar
• HAROUSSEAU JL, ATTAL M, LELEU X et al.: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM Phase II study. Haematologica (2006) 91(11):1498-1505.
   PubMed Web of Science ®Google Scholar
• MATEOS MV, HERNANDEZ JM, HERNANDEZ MT et al.: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter Phase 1/2 study. Blood (2006) 108(7):2165-2172.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, BERGSAGEL PL, KUEHL WM, ANDERSON KC: Advances in biology of multiple myeloma: clinical applications. Blood (2004) 104(3):607-618.
   PubMed Web of Science ®Google Scholar
• YASUI H, HIDESHIMA T, RICHARDSON PG, ANDERSON KC.: Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br. J. Haematol. (2006) 132(4):385-397.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, CATLEY L, YASUI H et al.: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 107(10):4053-4062.
   PubMed Web of Science ®Google Scholar
• RICHARDSON P, LONIAL S, JAKUBOWIAK J et al.: A multicenter Phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM). Blood (2006) 108(11) abstract.
   PubMedGoogle Scholar
• PODAR K, RAAB MS, ZHANG J et al.: Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor Enzastaurin (LY317615.HCl). Blood (2007) 109(4):1669-1677.
   PubMed Web of Science ®Google Scholar
• MITSIADES N MITISADES N, McMULLAN C et al.: The mTOR inhibitor RAD001 (Everolimus) is active against multiple myeloma cells in vitro and in vivo. Blood (2004) 104(11):1496.
   Web of Science ®Google Scholar
• SHI Y, GERA J, HU L et al.: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. (2002) 62(17):5027-5034.
   PubMed Web of Science ®Google Scholar
• RAJE N, KUMAR S, HIDESHIMA T et al.: Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood (2004) 104(13):4188-4193.
   PubMed Web of Science ®Google Scholar
• FRANCIS LK, ALSAYED Y, LELEU X et al.: Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin. Cancer Res. (2006) 12(22):6826-6835.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, PODAR K, CHAUHAN D et al.: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene (2004) 23(54):8766-8776.
   PubMed Web of Science ®Google Scholar
• SIEGEL D, KRISHNAN A, LONIAL S et al.: Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM). Blood (2006) 108(11).
   PubMedGoogle Scholar
• HU L, SHI Y, HSU JH, GERA J, VAN NESS B, LICHTENSTEIN A: Downstream effectors of oncogenic ras in multiple myeloma cells. Blood (2003) 101(8):3126-3135.
   PubMed Web of Science ®Google Scholar
• MITSIADES CS, MITSIADES NS, MCMULLAN CJ et al.: Antimyeloma activity of heat shock protein-90 inhibition. Blood (2006) 107(3):1092-1100.
   PubMed Web of Science ®Google Scholar
• RICHARDSON P, CHANAN-KHAN A, ALSINA M et al.: Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): interim results of a Phase 1 trial. Blood (2005).
   Google Scholar
• MITSIADES CS, MITSIADES N, ROONEY M et al.: IPI-504: A novel hsp90 inhibitor with in vitro and in vivo anti-tumor activity. ASH Annual Meeting Abstracts. Blood ASH Annual Meeting Abstracts (2004) 104(11):2403.
   Google Scholar
• CHANAN-KHAN AA, RICHARDSON PG, ALSINA M et al.: Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM). Blood Annual Meeting Abstracts. (2005) 106(11):362.
   Google Scholar
• AMIT-VAZINA M, SHISHODIA S, HARRIS D et al.: Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br. J. Cancer (2005) 93(1):70-80.
   PubMed Web of Science ®Google Scholar
• HAMASAKI M, HIDESHIMA T, TASSONE P et al.: Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro[4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood (2005) 105(11):4470-4476.
   PubMed Web of Science ®Google Scholar
• CHAUHAN D, VELANKAR M, BRAHMANDAM M et al.: A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene (2006) (In Press).
   Google Scholar
• HIDESHIMA T, BRADNER JE, WONG J et al.: Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. USA (2005) 102(24):8567-8572.
   PubMed Web of Science ®Google Scholar
• CHAUHAN D, CATLEY L, LI G et al.: A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 8(5):407-419.
   PubMed Web of Science ®Google Scholar
• MITSIADES CS, MITSIADES NS, MCMULLAN CJ et al.: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA (2004) 101(2):540-545.
   PubMed Web of Science ®Google Scholar
• TAI YT, TONG X, SANTOS D et al.: Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. (2005) 65(13):5898-5906.
   PubMed Web of Science ®Google Scholar
• HUSSEIN M, NIESVIZKY R, MUNSHI N et al.: A Phase I, multi-dose, dose escalation study of SGN-40 (anti-huCD40 mAb) in patients with refractory or recurrent multiple myeloma. J. Clin. Oncol. (ASCO Ann. Meet. Proc.) (2005) 23(6S):6581.
   Google Scholar
• HUSSEIN M, BERENSON J, NIESVIZKY R et al.: Results of a Phase I trial of SGN-40 (Anti-huCD40 mAb) in patients with relapsed multiple myeloma. Blood (2006) 108(11).
   PubMedGoogle Scholar
• BENSINGER W, JAGANNATH A, BECKER P et al.: A Phase 1 dose escalation study of a fully human, antagonist anti-CD40 antibody, HCD122 (Formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma. Blood (2006) 108(11).
   Google Scholar
• SAN MIGUEL JF, GONZALEZ M, GASCON A et al.: Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br. J. Haematol. (1991) 77(2):185-190.
   PubMed Web of Science ®Google Scholar
• TREON SP, PILARSKI LM, BELCH AR et al.: CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J. Immunother. (2002) 25(1):72-81.
   PubMed Web of Science ®Google Scholar
• MOREAU P, VOILLAT L, BENBOUBKER L et al.: Rituximab in CD20 positive multiple myeloma: a prospective study from the IFM group. Blood (2006) 108(11).
   Google Scholar
• ROODMAN GD: Pathogenesis of myeloma bone disease. Blood Cells Mol. Dis. (2004) 32(2):290-292.
   PubMed Web of Science ®Google Scholar
• ROODMAN GD: Mechanisms of bone metastasis. N. Engl. J. Med. (2004) 350(16):1655-1664.
   PubMed Web of Science ®Google Scholar
• BODY JJ, FACON T, COLEMAN RE et al.: A study of the biological receptor activator of NF-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. (2006) 12(4):1221-1228.
   PubMed Web of Science ®Google Scholar
• TIAN E, ZHAN F, WALKER R et al.: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. (2003) 349(26):2483-2494.
   PubMed Web of Science ®Google Scholar
• YACCOBY S, LING W, ZHAN F, WALKER R, BARLOGIE B, SHAUGHNESSY JD Jr: Antibody-based inhibition of DKK1 suppresses tumor- induced bone resorption and multiple myeloma growth in vivo. Blood (2006) (In Press).
   Google Scholar